Halozyme Therapeutics (HALO) Misses Q3 EPS by 2c
Tweet
Share
E-mailGet Alerts HALO Hot Sheet
Price: $112.56 -2.23%
Revenue Growth %: +36.2%
Financial Fact:
Operating income (loss): -22.74M
Today's EPS Names:
OCCI, ALZN, ASPU, More
Revenue Growth %: +36.2%
Financial Fact:
Operating income (loss): -22.74M
Today's EPS Names:
OCCI, ALZN, ASPU, More
Join SI Premium – FREE
Halozyme Therapeutics (NASDAQ: HALO) reported Q3 EPS of ($0.16), $0.02 worse than the analyst estimate of ($0.14). Revenue for the quarter came in at $14.6 million versus the consensus estimate of $16.5 million.
For earnings history and earnings-related data on Halozyme Therapeutics (HALO) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Paychex (PAYX) Tops Q1 EPS by 2c
- General Mills beats estimates as cost savings offset volumes
- AutoZone (AZO) PT Lowered to $4,230 at UBS Following 'Underwhelming' Q4 Print
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
